Calluna Pharma Reaches Key Milestone in IPF Development
Calluna Pharma has announced the successful completion of patient enrollment in its Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis (IPF) — more than six months ahead of schedule, underscoring strong execution and growing momentum for the program.
The global, randomized Phase 2 study enrolled 161 IPF patients across more than 50 sites in the US, Europe, the UK, Turkey, and South Korea. CAL101 is a first‑in‑class monoclonal antibody targeting S100A4, an upstream driver of fibrotic and inflammatory pathways, with the ambition to preserve lung function in patients living with this serious and progressive disease.
Completing enrollment well ahead of plan is a significant operational milestone and reflects strong engagement from investigators and patients worldwide. The AURORA study is designed to assess the efficacy and safety of CAL101, with topline data expected in the first quarter of 2027.
This achievement marks another important step forward for Calluna Pharma as it advances innovative, disease‑modifying therapies for fibrotic diseases — an ambition closely aligned with Sarsia’s focus on backing bold science with the potential for meaningful patient impact.
Read more here.